References
- Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990: 323(14): 946–55
- Blankenhom DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987: 257(23): 3233–40 [erratum, JAMA 1988: 259(18): 2698]
- Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990: 323(19): 1289–98
- Hodis HN. Acute hepatic failure associated with the use of low-dose sustained-release niacin. (Letter) JAMA 1990: 264(2): 181
- Duffield RG, Miller NE, Jamieson CW, et al. A controlled trial of plasma lipid reduction in peripheral atherosclerosis: an interim report. Br J Surg 1982: 69(Suppl): S3–5
- Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984: 69(2): 313–24
- Amtzenius AC, Kromhout D, Barth JD, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis: the Leiden Intervention Trial. N Engl J Med 1985: 312(13): 805–11
- Ornish DM, Scherwitz LW, Brown SE, et al. Adherence to lifestyle changes and reversal of coronary atherosclerosis. Circulation 1989: 80(Oct Suppl II): II–57
- Chesebro JH, Webster MW, Smith HC et al. Antiplatelet therapy in coronary disease progression reduced infarction and new lesion formation. Circulation 1989: 80(4 Suppl II): II–266
- Lichtlen PR, Hugenholtz P, Rafflenbeul W, et al. Retardation of the progression of coronary artery disease with nifedipine: results of INTACT. Circulation 1989: 80(4 Suppl II): II–382
- Deupree RH, Fields RI, McMahan CA, et al. Atherosclerotic lesions and coronary heart disease: key relationships in necropsied cases. Lab Invest 1973: 28(2): 252–62
- The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984: 251(3): 351–64
- Frick MH, Ho O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987: 317(20): 1237–45
- Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986: 8(6): 1245–55